Clinical Trial

Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Name: Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia — clinical trial record (NCT06118788)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a single-arm, single-dose dose-escalation and dose-expansion study.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2023-11-01; most recent amendment 2025-04-15.

Status change: Not Yet Recruiting → Recruiting 2024-03-27

Trial Details

NCT Number	NCT06118788
Lead Sponsor	Guangzhou Bio-gene Technology Co., Ltd
Conditions	Leukemia, Myeloid, Acute
Enrollment	24 participants
Start Date	2024-03-07
Primary Completion	2027-03 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2025-04-17